ACROBiosystems & DAAN partner to advance immunotherapies

ACROBiosystems, a leading global biotechnology company, signed a strategic Memorandum of Understanding (MoU) with DAAN Biotherapeutics, a clinical-stage biotech focused on precision immuno-oncology, to expedite the development and commercialization of future-proof immunotherapies.

The collaboration defines a multi-aspect platform consisting of solid supply of high-performance bioreagents, technical partnership to develop drugs, and collaborative research and data sharing. The two firms have set their goal to break current barriers in immunotherapy through the integration of ACROBiosystems' high-performance bioreagent and GMP-grade raw material expertise with DAAN's proprietary immune-modulation platform.

Key Highlights:

• ACROBiosystems signs MoU with DAAN Biotherapeutics to accelerate precision immunotherapy development and commercialization
• Collaboration covers bioreagent supply, drug development, and joint research, combining ACRO’s GMP expertise with DAAN’s immune-modulation platform
• Leaders expect global impact, with DAAN CEO Byoung Chul Cho citing faster transition to clinical trials and ACRO Korea head Yong Chan Cho calling it a landmark for Korean biotech

“ACROBiosystems is a quality-driven partner with the ability of technological innovation. This alliance will not only improve our effectiveness in the transition from preclinical to clinical development but also advance our expansion into global clinical trials more quickly.” stated Byoung Chul Cho, CEO of DAAN Biotherapeutics.

ACROBiosystems offers recombinant proteins, antibodies, kits, and scientific services with a core emphasis on cell and gene therapy solutions through its Resilient Supply model. Its GMP Manufacturing Base with dual ISO 9001/GMP certification provides audit-ready compliance and bulk supply of key raw materials.

Also Read: Geriatric Medicine Boom: Asia's Stunning Growth and Opportunities

DAAN Biotherapeutics, on the other hand, is working on an immune-modulation platform that selectively engages T cells inside the tumor microenvironment in order to lower toxicity and resistance to regular treatments. Its pipelines currently have its lead program in preclinical trials and pending global clinical trials, with further potential in autoimmune and rare diseases.

“This partnership with DAAN Biotherapeutics represents a very significant strategic landmark. We are anticipating this alliance to create synergistic benefits not just in precision therapeutics, but also to the rest of the Korean biotech sector.” added Yong Chan Cho, Country Manager of ACROBiosystems Korea.